Statin use and the risk of breast cancer
Statin use and the risk of breast cancer
复制标题
DOI：
10.1016/s0895-4356(02)00614-5
复制
发表时间：
2003-03-01
影响因子：
7.2
通讯作者：
Butler-Jones, D
中科院分区：
文献类型：
--
作者：
Beck, P;Wysowski, DK;Butler-Jones, D
该研究的目的是调查他汀类药物使用与乳腺癌（BRCA）之间的可能关联。采用基于萨斯喀彻温省人口健康服务数据库的历史队列设计。所有符合条件的1989年至1997年中期服用大于或等于1次他汀类药物的妇女和年龄性别匹配的未暴露组随访至8.5年（平均4.2年）。BRCA的相对发生率（RR）根据年龄、他汀类药物暴露时间和既往激素使用情况进行估计和分层。确定了13592名他汀类药物使用者和53880名未暴露的受试者。共发现879例突发BRCA病例。在小于或等于55岁的女性中，他汀类药物与BRCA风险无关。在年龄0 ~ 55岁的受试者中，BRCA的RR为1.15（0.97,1.37）。分层分析显示，短期他汀类药物使用者和长期激素替代治疗（HRT）的他汀类药物使用者的风险增加。需要更多的研究来确定短期使用他汀类药物和长期使用他汀类药物是否会增加绝经后BRCA的风险。Elsevier Science Inc.出版。
The study objective was to investigate a possible association between statin use and breast cancer (BRCA). An historical cohort design based on Saskatchewan's population health services databases was used. All eligible women with greater than or equal to1 statin prescription from 1989 to mid-1997 and an age-sex-matched nonexposed group were followed up to 8.5 years (mean 4.2 years). Relative rates (RR) of BRCA were estimated and stratified by age, statin exposure time, and prior hormone use. Thirteen thousand five hundred ninety-two statin users and 53,880 nonexposed subjects were identified. Eight hundred seventy-nine incident BRCA cases were identified. Statins were not associated with BRCA risk in women less than or equal to55 years. Among subjects >55 years, the RR for BRCA was 1.15 (0.97, 1.37). Stratified analyses revealed increases in risk in short-term statin users and statin users with long-term hormone replacement therapy (HRT) exposure. More studies are needed to determine if short-term statin use and statin use with long-term HRT exposure increases postmenopausal BRCA risk. Published by Elsevier Science Inc.